Germline Mutations clinical trials

Explore recruiting germline mutations clinical trials.

Recruiting germline mutations studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Germline Mutations trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.A Belgian Precision 2 study

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early “triple negative” breast cancer

Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite instability high (MSI-H) oEso-gastric junction and gastric adenocarcinoma: A two cohort open-label GERCOR phase II study

France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation

Spain, Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Germline Mutations trials by city

Germline Mutations in Toronto Germline Mutations in Vancouver Germline Mutations in Montreal Germline Mutations in Calgary Germline Mutations in Edmonton Germline Mutations in Ottawa Germline Mutations in Winnipeg Germline Mutations in Quebec City Germline Mutations in Hamilton Germline Mutations in Kitchener Germline Mutations in London Germline Mutations in Halifax Germline Mutations in New York Germline Mutations in Los Angeles Germline Mutations in Chicago Germline Mutations in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease